Home › NCT05090345

A Prospective Registry of Pediatric Cellular Therapy Patients at Risk for Endothelial Dysfunction, Sinusoidal Obstruction Syndrome and/or Multi-Organ Dysfunction Syndrome (MODS).

Prospective Multi Center Study of Pediatric Cellular Therapy Patients at Risk for Endothelial Dysfunction, Sinusoidal Obstruction Syndrome and/or Multi-Organ Dysfunction Syndrome (MODS)

Who can join

Ages 0 to 26 · All sexes

Inclusion Criteria:

* Children, adolescents and young adults (AYA) 0-26 years of age undergoing HSCT.
* Recipients of autologous and allogeneic HSCT.
* Any preparative regimen.

Exclusion Criteria:

* Any patient who does not consent/assent to participation.
* Any patient for whom 5 mL blood sample(s) drawn at specified intervals would pose any more than minimal risk, as defined by institutional guidelines and at discretion of treating physician will be ineligible for biorepository banking.

About the study

This is a prospective international multi-center registry and biorepository trial of children and adolescents/young adults (AYA) undergoing hematopoietic cell transplantation (HCT) to assess the impact of endotheliopathies in the HCT setting as a contributor of significant morbidity and mortality.

What is being tested

• Biorepository Trial (other)

Sponsor: Duke University · Participants: 500 · Started: Nov 19, 2019

Contact the study team

• LaTarsha Spencer · Phone: (919) 613-1895

Official record on ClinicalTrials.gov — NCT05090345

Locations in the U.S.

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.